Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevnetm (bevacizumab-nwgd), ...

Biocon Biologics, a subsidiary of Biocon Ltd, announced on Thursday that it has received approval from the United States Food ...

Biocon Biologics (BBL), a subsidiary of Biocon, today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous ...

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...

Biocon Biologics Limited (BBL) announced on Thursday that it had received approval from the United States Food and Drug ...

Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various ...

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable ...

Announced an agreement with F. Hoffmann-La Roche Ltd. (Roche) to advance the evaluation of amezalpat in combination with atezolizumab and bevacizumab into a pivotal Phase 3 trial for the first-line ...

Bone regeneration continues to be a critical challenge in tissue engineering, with unpredictable outcomes often hindering clinical application. Current strategies overlook key factors such as donor ...

Increased dietary folic acid intake may lead to adverse health effects, including inflammation and neurotoxicity, ...